Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Cyclodiol

From Wikipedia, the free encyclopedia
Cyclodiol
Clinical data
Other namesZK-115194; Cycloestradiol; 14α,17α-Ethano-17β-estradiol; 14α,17α-Ethanoestra-1,3,5(10)-triene-3,17β-diol; 14,21-Cyclo-19-norpregna-1,3,5(10)-triene-3,17α-diol
Routes of
administration
By mouth[1]
Drug classEstrogen
Pharmacokinetic data
Bioavailability33 ± 19%[1]
Elimination half-life28.7 hours[1]
Identifiers
  • (8R,9S,13S)-13-Methyl-7,8,9,11,12,13,15,16-octahydro-14,17-ethanocyclopenta[a]phenanthrene-3,17(6H)-diol
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H26O2
Molar mass298.426 g·mol−1
3D model (JSmol)
  • C[C@]12CC[C@H]3[C@H](C14CCC2(CC4)O)CCC5=C3C=CC(=C5)O
  • InChI=1S/C20H26O2/c1-18-7-6-16-15-4-3-14(21)12-13(15)2-5-17(16)19(18)8-10-20(18,22)11-9-19/h3-4,12,16-17,21-22H,2,5-11H2,1H3/t16-,17-,18+,19?,20?/m1/s1
  • Key:YGXXZMDWSWSCSI-UYUJGIFYSA-N

Cyclodiol (developmental code name ZK-115194; also known as 14α,17α-ethano-17β-estradiol) is a synthetic estrogen which was studied in the 1990s and was never marketed.[2][1][3] It is a derivative of estradiol with a bridge between the C14α and C17α positions.[2][1][3][4] Cyclodiol has 100% of the relative binding affinity of estradiol for the human ERα and similar transactivational capacity as estradiol at the receptor.[2] It has comparable potency to estradiol when administered by subcutaneous injection.[2] The drug shows genotoxicity similarly to estradiol.[2][4] Cyclodiol showed an absolute bioavailability of 33 ± 19% and an elimination half-life of 28.7 hours in pharmacokinetic studies in women.[1]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 Baumann A, Fuhrmeister A, Brudny-Klöppel M, Draeger C, Bunte T, Kuhnz W (October 1996). "Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women". Contraception. 54 (4): 235–242. doi:10.1016/S0010-7824(96)00194-1. PMID 8922877.
  2. 1 2 3 4 5 Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 10, 15, 76, 329, 332. ISBN 978-3-642-60107-1.
  3. 1 2 Lang R, Reimann R (1993). "Studies for a genotoxic potential of some endogenous and exogenous sex steroids. I. Communication: examination for the induction of gene mutations using the Ames Salmonella/microsome test and the HGPRT test in V79 cells". Environmental and Molecular Mutagenesis. 21 (3): 272–304. Bibcode:1993EnvMM..21..272L. doi:10.1002/em.2850210311. PMID 8462531. S2CID 39049586.
  4. 1 2 Hundal BS, Dhillon VS, Sidhu IS (March 1997). "Genotoxic potential of estrogens". Mutation Research. 389 (2–3): 173–181. Bibcode:1997MRGTE.389..173H. doi:10.1016/S1383-5718(96)00144-1. PMID 9093381.